Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to alleged violations of federal securities laws related to misleading statements about the efficacy of its drug setrusumab for Osteogenesis Imperfecta [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Ultragenyx to contact them directly to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Ultragenyx [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives made false and misleading statements regarding the effects of setrusumab, creating a false impression of reliable information while downplaying risks associated with the Phase III Orbit study [4]. - Ultragenyx's optimism regarding the Phase III Orbit study's results was deemed misplaced, as the company failed to adequately disclose risks related to the study's Phase II results, which lacked a placebo control group [4]. Group 3: Stock Performance Impact - On July 9, 2025, Ultragenyx announced that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [5]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [6][7].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly providing misleading information regarding the efficacy of its drug setrusumab during clinical trials, leading to inflated stock prices for investors [1][5][6]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Ultragenyx common stock between August 3, 2023, and December 26, 2025 [1]. - The lawsuit claims that Ultragenyx's management made overly positive statements about setrusumab's ability to reduce fracture rates in Osteogenesis Imperfecta patients while concealing material adverse facts [5][6]. - It is alleged that the Phase III studies were less likely to demonstrate the claimed efficacy than management suggested, resulting in investors purchasing shares at artificially inflated prices [6]. Group 2: Legal Representation - Investors who purchased Ultragenyx stock during the class period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][7]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to alleged violations of federal securities laws related to misleading statements about clinical trial results [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $100,000 in Ultragenyx between August 3, 2023, and December 26, 2025, to contact them for legal options [1]. - A federal securities class action has been filed against Ultragenyx, with a deadline of April 6, 2026, for investors to seek the role of lead plaintiff [4]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives misled investors by creating a false impression of reliable information regarding the effects of setrusumab on patients with Osteogenesis Imperfecta, while downplaying the risks of clinical trial failures [6]. - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [7]. - On December 29, 2025, Ultragenyx announced that both the Phase III Orbit and Cosmic Studies failed to meet primary endpoints, resulting in a further stock price decline of more than 42% [8][9].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly providing misleading information regarding the efficacy of its drug setrusumab during clinical trials, leading to inflated stock prices for investors who purchased shares between August 3, 2023, and December 26, 2025 [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx's management made overly positive statements about setrusumab's ability to reduce fracture rates in Osteogenesis Imperfecta patients while concealing material adverse facts about the drug's actual efficacy [5][6]. - It is alleged that the Phase III Orbit and Cosmic studies were less likely to demonstrate the claimed benefits than management suggested, which misled investors [6]. Group 2: Investor Information - Investors who purchased Ultragenyx common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][7]. Group 3: Law Firm Credentials - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. for the period between August 3, 2023, and December 26, 2025, due to alleged misleading statements regarding the company's drug setrusumab [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx provided investors with overly positive information about the expected results of its Phase III Orbit and Cosmic Studies for setrusumab, which is intended for treating Osteogenesis Imperfecta (OI) [5]. - Defendants allegedly made materially false and misleading statements about setrusumab's potential, claiming it would decrease the annualized fracture rate in OI patients, while concealing the true risks and limitations of the study protocols [6]. - The lawsuit asserts that these misleading statements led to Ultragenyx securities being purchased at artificially inflated prices, resulting in investor damages when the true information became public [6]. Group 2: Participation in the Class Action - Investors who purchased Ultragenyx common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][7]. - A lead plaintiff must be appointed by April 6, 2026, to represent the interests of other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Insights - Ultragenyx is accused of misleading investors regarding the potential success of setrusumab's Phase 3 study in reducing fracture rates [1] Company Summary - The allegations suggest that Ultragenyx may have provided inaccurate information about the efficacy of setrusumab, which could impact investor confidence and stock performance [1]

Core Insights - The upcoming year is a pivotal moment for the company, with two potential product launches and a crucial data readout expected to significantly boost commercial revenue [1] - A strategic restructuring plan is being implemented to lower operating expenses and align resources with high-impact opportunities in the rare disease sector [2] FDA Update - The company received an Incomplete Response Letter (IRL) from the FDA regarding its resubmitted marketing application for UX111 (rebisufligene etisparvovec) gene therapy for Sanfilippo syndrome type A, requesting additional documentation for resubmission [3] Earnings Snapshot - The company reported a fourth-quarter loss of $1.29 per share, missing the consensus estimate of $1.14, while sales increased to $207 million from $165 million year-over-year, surpassing the consensus of $196.97 million [4] - Revenue from Crysvita was $145 million, Dojolvi reached $32 million, and Evkeeza sales were $17 million [4] Strategic Restructuring - A strategic restructuring plan has been initiated, including a 10% workforce reduction affecting approximately 130 employees, aimed at reducing expenses and partially reinvesting to support future growth [5] - The company aims to achieve profitability by 2027 through significant cost discipline and revenue growth from current and new product launches [5] Outlook - The company forecasts fiscal 2026 sales between $730 million and $760 million, below the consensus of $786.93 million, with Crysvita revenue expected to be between $500 million and $520 million and Dojolvi revenue projected at $100 million to $110 million [6] Market Reaction - Following the announcements, Ultragenyx Pharmaceutical shares fell by 10.21% to $21.10 [7]

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged misleading statements regarding the efficacy of its drug setrusumab, impacting investors who purchased shares between August 3, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made false statements about setrusumab's ability to reduce fracture rates despite increasing bone density, which misled investors [5]. - Investors who purchased shares during the specified period may be eligible for compensation without incurring out-of-pocket costs through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking highly in the industry since 2013 [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged misleading statements regarding the potential of setrusumab and its study protocols, impacting investors who purchased stock between August 3, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made false and/or misleading statements about setrusumab's ability to increase bone density and its correlation with fracture rates, which were misrepresented to investors [5]. - Investors who purchased common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Insights - Ultragenyx reported $207 million in revenue for Q4 2025, marking a year-over-year increase of 25.6% [1] - The company's EPS for the same period was -$1.29, an improvement from -$1.39 a year ago, but below the consensus estimate of -$1.20 [1] - The revenue exceeded the Zacks Consensus Estimate of $202.92 million by 2.01%, while the EPS fell short by 7.32% [1] Revenue Breakdown - Dojolvi generated $32 million in revenue, surpassing the average estimate of $30.28 million, with a year-over-year increase of 2.9% [4] - Evkeeza achieved $17 million in revenue, exceeding the estimated $16.37 million, reflecting a significant year-over-year growth of 63.9% [4] - Mepsevii reported $13 million in revenue, above the average estimate of $10.81 million, also showing a year-over-year increase of 63% [4] - Total Crysvita revenue reached $145 million, exceeding the average estimate of $135.25 million [4] - Overall product sales were $102 million, which was below the estimated $114.76 million, but still represented a year-over-year increase of 41.9% [4] - Royalty revenue amounted to $105 million, surpassing the average estimate of $91.57 million, with a year-over-year change of 12.9% [4] Stock Performance - Over the past month, Ultragenyx shares have returned -0.8%, compared to a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]